Roland Magnusson/iStock Editorial via Getty Images
AstraZeneca (AZN) posted stronger-than-expected Q3 results, fueled by continued strength in its oncology portfolio. The U.K. drugmaker reported adjusted EPS of $2.38, well above the $1.13 consensus, while revenue rose 11.9% year-over-year to $15.19B, topping estimates by $420M.
Oncology product sales
Remember those teenage years when we first began to question ourselves, trying to figure out how to connect, or disconnect,...
The semiconductor company and the electronics manufacturing firm, respectively, will replace Pool Corp. and The Campbell’s Company before the start...
In the midst of unprecedented national division, Republicans and Democrats have apparently found something upon which they agree: that US...
The pharmaceutical industry is highly competitive and driven by innovation. Those two facts couldn't be on any clearer display than...
Trade jobs are having a moment. Touted as the smarter, safer alternative to “irrelevant” overpriced degrees and entry-level white-collar jobs...
Remember when vaping was first introduced, and people rushed to exchange their cigarettes for vapes because it was supposed to...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
-1024x768.jpg "Red Snapper Used as Cudgel by Fed Judge")
